Gubra A/S
CSE:GUBRA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
114
726
|
Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Gubra A/S
Other Current Liabilities
Gubra A/S
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
G
|
Gubra A/S
CSE:GUBRA
|
Other Current Liabilities
kr61.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Chemometec A/S
CSE:CHEMM
|
Other Current Liabilities
kr84.3m
|
CAGR 3-Years
11%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
Gubra A/S
Glance View
Gubra ApS operates as biotechnology company. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The firm's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
See Also
What is Gubra A/S's Other Current Liabilities?
Other Current Liabilities
61.9m
DKK
Based on the financial report for Dec 31, 2023, Gubra A/S's Other Current Liabilities amounts to 61.9m DKK.
What is Gubra A/S's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
7%
Over the last year, the Other Current Liabilities growth was -17%. The average annual Other Current Liabilities growth rates for Gubra A/S have been 7% over the past three years .